Skip to content

Efficacy of a oil Containing Chamomile in the Treatment Atopic Dermatitis

Efficacy of a oil Containing Chamomile in the Treatment of Mild to Moderate Atopic Dermatitis: A Randomized, Double-blind controlled Trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180108038274N1
Enrollment
52
Registered
2018-04-19
Start date
2018-03-20
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis. Atopic dermatitis, unspecified

Interventions

Intervention 1: Intervention group:Chamomile oil twice a day for 14 days. Intervention 2: Control group:Oceerin twice a day for 14 days.

Sponsors

Sabzevar University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: Infants with atopic dermatitis (based on SCORAD criteria and pediatrician diagnosis) Good birth weight for age Lack of underlying diseases and congenital disorders. Inclination mother's cooperation With the plan

Exclusion criteria

Exclusion criteria: Major medical diseases (immunodeficiency, growth and development disorders, genetic disorders) The presence of skin lesions other than eczema in the areas of topical application of the drug Use of medications that affect eczema during maternal or infant use Cancellation of the patient to continue the study

Design outcomes

Primary

MeasureTime frame
The severity of the involvement of dermatitis. Timepoint: Before starting treatment and on days 6, 13, 27. Method of measurement: Questionnaire and with SCORAD criteria for atopic dermatitis.;The dryness, redness and irritation. Timepoint: Before starting treatment and on days 6, 13, 27. Method of measurement: Questionnaire.;Pruritus rate. Timepoint: Before starting treatment and on days 6, 13, 27. Method of measurement: Questionnaire.;Insomnia and restlessness of infants. Timepoint: Before starting treatment and on days 6, 13, 27. Method of measurement: Questionnaire.

Secondary

MeasureTime frame
Quality of Life. Timepoint: Before starting treatment and days 6, 13 and 27. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNeda Sirghani

Sabzevar University of Medical Sciences

nedasirghani@yahoo.com+98 51 4426 4588

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026